Welcome to our dedicated page for Prophase Labs news (Ticker: PRPH), a resource for investors and traders seeking the latest updates and insights on Prophase Labs stock.
ProPhase Labs Inc (NASDAQ: PRPH) delivers cutting-edge solutions across diagnostics, genomics, and consumer health products. This news hub provides investors and industry observers with essential updates on the company’s scientific advancements, financial performance, and market initiatives.
Access authoritative reports on PRPH’s latest developments, including earnings announcements, strategic partnerships, and innovations in AI-driven diagnostic testing. Our curated collection ensures you stay informed about regulatory milestones, product launches, and research breakthroughs shaping the company’s trajectory.
Explore updates across key categories: quarterly financial results, FDA clearances, clinical trial progress, and consumer product expansions. Bookmark this page for real-time insights into how ProPhase Labs continues merging medical science with accessible health solutions through its dual focus on institutional diagnostics and consumer genomics.
ProPhase Labs (NASDAQ: PRPH) reports significant growth in PCR COVID-19 testing volumes, exceeding 300,000 tests in Q4 2021, a sharp increase from about 110,000 in Q1 2021. The rise is attributed to a growing customer base and the emergence of the Omicron variant. The company expanded its workforce, increasing lab personnel from 50 to over 250 to meet demand while maintaining average result turnaround times of under 48 hours. Looking ahead, ProPhase anticipates ongoing growth across its testing and genomic services throughout 2022.
ProPhase Labs (Nasdaq: PRPH) announces that CEO Ted Karkus will present a corporate overview at the H.C. Wainwright Bioconnect 2022 Virtual Conference, scheduled for January 10-13, 2022. The presentation will be available on-demand for registered attendees starting at 7:00 a.m. ET on January 10.
ProPhase Labs is a diversified biotech company focusing on genomics and CLIA lab services, including COVID-19 testing, whole genome sequencing, and genetic research.
ProPhase Labs (NASDAQ: PRPH) has appointed Sam A. Beeler as Chief Strategy Officer while promoting Alice Lioi and Jason Karkus to Executive Vice Presidents/Co-Chief Operating Officers, and Sergio Miralles to Executive Vice President/Chief Information Officer. CEO Ted Karkus highlighted Beeler's role in enhancing Nebula Genomics' presence in personalized medicine and securing lower Whole Genome Sequencing prices. The promotions recognize the leadership of Lioi, Karkus, and Miralles in developing ProPhase Diagnostics and expanding its lab services.
ProPhase Labs, Inc. (Nasdaq: PRPH) announced the grant of a stock option to a new employee, consisting of 100,000 shares of common stock. This inducement award was made under Nasdaq Rule 5635(c)(4), not within the company's equity plan. The exercise price is set at $5.76 per share, equal to the stock’s closing price on November 19, 2021. Vesting occurs over four years, starting with 25% on the grant date, and the option has a term of seven years. ProPhase, a diversified biotech firm, focuses on genomics and diagnostic services, including COVID-19 testing.
ProPhase Labs, Inc. (NASDAQ: PRPH) reported a strong financial performance for Q3 2021, achieving $9.5 million in total revenue, a 150% increase from $3.8 million in Q3 2020. The company performed 57,000 diagnostics tests in the quarter but reported a net loss of $4.0 million or $(0.26) per share. Cash and equivalents stood at $22.9 million with net working capital of $34.0 million. ProPhase acquired Nebula Genomics for $14.6 million and is optimistic about increasing testing volumes and expanding its diagnostics business.
ProPhase Labs (Nasdaq: PRPH) announces that Chairman and CEO Ted Karkus will present at the virtual Q4 Investor Summit Conference on November 16, 2021, at 2:00 PM ET. The conference runs from November 16-17, 2021, and investors can register online. Karkus will also be available for one-on-one meetings during the event.
ProPhase Labs focuses on genomics testing, COVID-19 testing, and consumer healthcare products. The company aims to leverage its CLIA lab services for whole genome sequencing and has a broad range of diagnostic services.
ProPhase Labs, Inc. (NASDAQ: PRPH) will hold a conference call on November 12, 2021, at 11:00 a.m. ET to discuss Q3 results ending September 30, 2021. CEO Ted Karkus will lead the call, followed by a Q&A session. Registration is necessary to access the call, with a toll-free dial-in option available. ProPhase is a diversified biotech firm focused on genomic testing and CLIA lab services, including COVID-19 testing. The company aims to build a genomic database and expand its services internationally.
ProPhase Labs (NASDAQ: PRPH) announced a decline in expected Q3 2021 COVID-19 testing revenues due to lower summer testing rates. However, the company anticipates a rebound in Q4 2021, aiming to match record Q1 revenues driven by government mandates and an increasing customer base. CEO Ted Karkus noted heightened testing levels in October and ongoing organic growth. The integration of Nebula Genomics into ProPhase's operations is advancing as planned, promising faster genomic testing and lower prices, which may significantly boost sales in 2022.
GARDEN CITY, NY, Oct. 6, 2021 -- ProPhase Labs, Inc. (Nasdaq: PRPH) announces that Chairman and CEO Ted Karkus will present virtually at the 14th Annual LD Micro Main Event Conference. This presentation is scheduled for October 14, 2021, at 9:30 AM ET. ProPhase Labs is a diversified biotech and genomics company, leveraging its CLIA lab services for whole genome sequencing and COVID-19 testing. The company aims to expand its testing capabilities globally and enhance its genomics database for research purposes.
ProPhase Labs, Inc. (Nasdaq: PRPH) announced that CEO Ted Karkus will present at the Benzinga Healthcare Small Cap Conference, virtually held from September 29-30, 2021. Karkus's presentation is scheduled for September 29 at 2:20 PM ET. Investors can register for the conference online. ProPhase Labs is a diversified biotech and genomics company focused on whole genome sequencing and CLIA lab services, including COVID-19 testing. The firm also aims to expand its testing services internationally and enhance genomic data research.
FAQ
What is the current stock price of Prophase Labs (PRPH)?
What is the market cap of Prophase Labs (PRPH)?
